Dr. Jagannath on Potential of Immunotherapy in Multiple Myeloma

Sundar Jagannath, MD
Published: Monday, Mar 27, 2017



Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Cancer Center, discusses the potential impact of immunotherapy in multiple myeloma.

Immunotherapy approaches may overcome mutational burdens or drug resistance in the cancer cells of this disease, says Jagannath. Monoclonal antibodies such as daratumumab (Daralex) and elotuzumab (Empliciti) are being used in newly diagnosed patients with myeloma. Additionally, checkpoint inhibitors may move upfront if they show positive results in the relapsed setting.

According to Jagannath, immuno-oncology may have a huge impact on the treatment landscape of multiple myeloma.



Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Cancer Center, discusses the potential impact of immunotherapy in multiple myeloma.

Immunotherapy approaches may overcome mutational burdens or drug resistance in the cancer cells of this disease, says Jagannath. Monoclonal antibodies such as daratumumab (Daralex) and elotuzumab (Empliciti) are being used in newly diagnosed patients with myeloma. Additionally, checkpoint inhibitors may move upfront if they show positive results in the relapsed setting.

According to Jagannath, immuno-oncology may have a huge impact on the treatment landscape of multiple myeloma.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x